Investor Relations

About Certara

Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies.

View company overview

News releases

View all
Aug 04, 2026

A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.

Read more
Jul 15, 2026

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4 th, 2026.

Read more
Jul 07, 2026

New capabilities unify Certara's biosimulation software, products, datasets, and scientific expertise with AI-driven agents to deliver specialized insights for life sciences RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug

Read more